GlassScriptPhysician profile
Micaela Perkins
NPI 1598130114
$31,865.46
in general payments reported to CMS, 2019-2025
24 companies · $3,335 in 2025
The $3,335 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $9,342 · 2023: $3,497 · 2024: $3,861 · 2025: $3,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,581.91 |
| Education | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19,991.93 | 2021-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $3,075.35 | 2022-2025 | |
| Janssen Biotech, INC. | $1,312.46 | 2021-2025 | Tremfya, Remicade, Simponi |
| Novartis Pharmaceuticals Corporation | $1,273.78 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $920.73 | 2021-2025 | Ofev, Cyltezo |
| Ucb, INC. | $799.90 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $685.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $612.32 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $608.27 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $470.33 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $438.32 | 2021-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $344.39 | 2022-2024 | Acthar |
| Fresenius Kabi USA, LLC | $333.47 | 2023-2025 | Idacio, Tyenne |
| Organon LLC | $266.46 | 2023-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $216.53 | 2023-2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $122.70 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $87.04 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $81.34 | 2024-2025 | Orencia |
| Scilex Pharmaceuticals INC. | $67.13 | 2024-2025 | |
| Genentech USA, INC. | $50.41 | 2024-2025 | Actemra |
| Sobi, INC | $37.04 | 2021-2022 | |
| Mylan Institutional INC. | $35.04 | 2023 | Hulio |
| Hikma Pharmaceuticals USA | $21.11 | 2021 | |
| Sandoz INC. | $14.00 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micaela Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.